AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$WST

Favorite Annette F sold $2.7M of WST

Favorite Annette F (Sr. VP & Chief HR Officer) sold 7,524 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at an average of $355.03 ($345.00–$365.00, $2.67M total) across 3 trades over 2026-09-11 to 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Favorite Annette F
Published Sep 15, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WST
Neutral
high confidence
Mentioned
$WST
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WSTNeutralLow
01

Why it matters

Routine insider sale with limited market effect.

02

Market read

Low relevance; typical insider sale.

03

What to watch

None

Relevance 5/10Novelty 4/10Timing: filed Sep 15 2026

Background

Form 4 filing discloses insider transaction.

Company-level read

Ticker impact

$WSTNeutralHigh confidence
Context

Insider Sr. VP & Chief HR Officer sold 7,524 shares for $2.67M via 10b5-1 plan.

Expected impact

No significant price impact expected.

Evidence & confidence

Sale size is small relative to market cap and insider still holds 21,818 shares.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

None

Key entities

  • Company
    West Pharmaceutical Services Inc.

    Issuer of the shares sold.

  • Person
    Favorite Annette F

    Sr. VP & Chief HR Officer, insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WST insider trading history →

Related articles

OCT 31
$WSTHighAI 8/10

What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call

West Pharmaceutical Services reported Q3 revenue of $874M, up 8.7%, with adjusted EPS increasing 36% to $2.66. Strong demand for biologics and GLP-1 therapies drove growth, particularly in proprietary products. The company raised its 2026 outlook, forecasting revenue of $3.41B-$3.42B and adjusted EPS of $9.38-$9.48. West is also expanding HVP capacity and maintaining dividend and share repurchase programs.

finance.yahoo.com2 min
OCT 29
$WSTMed

West Pharmaceutical Services, Inc. Q3 2026 Earnings Call Summary

West Pharmaceutical Services reported Q3 2026 earnings, highlighting 16.6% growth in proprietary products, driven by HVP components and GLP-1 treatments. Gross margins expanded by 310 basis points due to a shift toward high-value products. The company raised full-year organic growth guidance to 11.3%-11.6% and announced an 18% dividend increase. Management discussed strategic shifts, including divestitures and capital investments in HVP capacity.

finance.yahoo.com6 min
OCT 29
$WSTMedAI 8/10

West Pharmaceutical Services Inc (WST) (Q3 2026) Earnings Call Highlights: Record Margins

West Pharmaceutical Services reported Q3 2026 earnings with record margins, but faced revenue declines in the West Vantage segment and a planned divestiture headwind. Free cash flow decreased 5% year-over-year. CEO Michel Lagarde emphasized strong organic growth prospects and high M&A criteria. GLP-1 revenue growth is expected to decelerate due to tough comparisons. The company anticipates continued margin expansion and plans to invest in high-return HVP areas.

finance.yahoo.com3 min